drug development

A unique collection of 3170 approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1440 hepatotoxicity causing compounds, a powerful tool for drug toxicity study, can be used for HTS and HCS screening;

A unique collection of 101 compounds with defined hematopoietic toxicity for high throughput and high content drug screening;

A unique collection of 701 preclinical compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 5084 compounds for high-throughput screening and high-content screening,

A unique collection of 692 compounds with antibiotic activity for new antibacterial drug screening;

3500 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 680 EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3000 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 325 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

A unique collection of 523 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening;

A unique collection of 1180 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 540 gut microbial metabolites which can be used for HTS and HCS;

A unique collection of 3064 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A collection of 19730 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of 2073 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1600 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;

A unique collection of 3177 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 4986 pure natural products and their derivatives with known biological activity for drug discovery, pharmacological study, stem cell differentiation, fingerprint study and quality research, and can be used for high throughput screen

A unique collection of 4225 natural products for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 500 natural alkaloids can be used for high throughput and high content screening;

A unique collection of 2534 natural product monomers that meet the "Lipinski's Rule of Five", a powerful tool for HTS and HCS screening;

A unique collection of 1812 natural products with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);